External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non‐anaplastic non‐medullary thyroid cancer. Issue 4 (24th June 2014)

• Record Type: Journal Article
• Authors: Romesser, Paul B.; Sherman, Eric J.; Shaha, Ashok R.; Lian, Ming; Wong, Richard J.; Sabra, Mona; Rao, Shyam S.; Fagin, James A.; Tuttle, R. Michael; Lee, Nancy Y.
• Is Part Of: Journal of surgical oncology. Volume 110:Issue 4(2014:Sep. 15)
• Page Start: 375
• Page End: 382
• Publication Date: 2014-06-24
• Subjects: Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.23656
• Languages: English
• ISSNs: 0022-4790

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jso23656-sec-0001" sec-type="section"> <title>Background and Objectives</title> <p>To review clinical outcomes and toxicities in locally advanced differentiated thyroid cancer patients treated with external beam radiotherapy (EBRT) with or without concurrent chemotherapy (CCRT).</p> </sec> <sec id="jso23656-sec-0002" sec-type="section"> <title>Methods</title> <p>Between 1990 and 2012, 66 patients with gross residual/unresectable non‐anaplastic non‐medullary thyroid cancer were treated with EBRT.</p> </sec> <sec id="jso23656-sec-0003" sec-type="section"> <title>Results</title> <p>The median overall survival was 42.0 months. The overall locoregional progression‐free survival (LPFS) at 3 years was 77.3%. CCRT resulted in a non‐significant improvement in LPFS (90.0% vs. 73.0%, <italic>P</italic> = 0.347). Poorly differentiated histology had significantly improved LPFS (89.4% vs. 66.1%, <italic>P</italic> = 0.020), despite a significantly worse distant metastasis‐free survival (43.9% vs. 82.5%, <italic>P</italic> = 0.023).</p> <p>Acute treatment‐related toxicity included dermatitis, mucositis, and dysphagia with grade three rates of 12.1%, 19.7%, and 16.7%, respectively. The incidence of late toxicity was low. CCRT was only associated with a significant greater rate of acute grade 3 hoarseness (10.0% vs. 0.0%, <italic>P</italic> = 0.033), but with no difference in the rate of grade 2 late toxicity.</p> </sec> <sec id="jso23656-sec-0004" sec-type="section"> <title>Conclusions</title> <p>EBRT is a safe and effective treatment modality with 90% LPFS at 3 years in patients with gross residual or unresectable non‐anaplastic, non‐medullary thyroid carcinoma treated with CCRT. Further incorporation of EBRT with concurrent chemotherapy may result in improved disease control. <italic>J. Surg. Oncol. 2014; 110:375–382</italic>. © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>